Sanofi’s Type 2 Diabetes Drug Demonstrates Positive Results in Late-stage Phase III Clinical Trials

Published By : 13 Jun 2016 | Published By : QYRESEARCH

The global market for diabetes treatment therapies, drugs, and medications has seen a significant rise in the past few years as the prevalence of diabetes has flared up at an alarming pace on the global front. The World Health Organization states that the prevalence of this lifestyle disease has increased from nearly 4.7% in 1980 to almost double, 8.5% in 2014, among adults aged more than 18 years. Over the same period, the number of diabetes patients has increased from nearly 108 mn to over 422 mn. Improper management and lack of precautions in diabetes lead to the death of millions every year across the globe.

It is the severity of the disease and the several complications it causes in the human body that it has become the focus of research of many international drug makers. International pharmaceutical companies are leveraging their efforts, increasing their funds, and actively researching towards the development of the most effective treatment to manage the condition.

One such effort, undertaken by the French pharma company Sanofi has recently demonstrated positive results in two late-stage phase III clinical trials.

The company recently mentioned that phase III trials of its diabetes drug LixiLan have met their targets and the drug is now ready for approval from authorized drug approval bodies in the United States in the Europe. The drug is due to undergo approval in the U.S. in August this year and in Europe at the start of the next year.

LixiLan is a single-injection drug made from the combination of Lyxumia, developed by the Danish company Zealand Pharma, and the Lantus developed by Sanofi. The drug is meant to treat patients suffering from type 2 diabetes, which accounts for over 90% of all the diabetic cases across the globe.

Both the clinical studies were able to meet their primary endpoints where the drug demonstrated excellent reduction of HbA1c, which is the count of average blood glucose over the past three months as compared to comparators. Sanofi has mentioned that the results have been included in the regulatory submission to the European Medicines Agency and the U.S. FDA.

The company is expecting that the drug will be approved in the U.S. in August and in the first quarter of next year in Europe.

Back To Top